Press Release

Publication of a Related Party Transaction pursuant to Article 111c of the AktG with the aim of European distribution

Carl Zeiss Meditec AG enters into a shareholder loan with Carl Zeiss AG to partially finance acquisition of D.O.R.C.

2 April 2024

Jena | April 2, 2024 | Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) entered into a loan agreement with Carl Zeiss AG, Oberkochen, Germany on April 2, 2024. Carl Zeiss AG directly and indirectly holds around 59% of shares in Carl Zeiss Meditec AG. Purpose of the loan is to partially finance the acquisition of Dutch Ophthalmic Research Center (International) BV, Zuidland, Netherlands (D.O.R.C.), as announced on Dec 15, 2023.

Under this loan agreement, Carl Zeiss Meditec AG receives an unsecured loan from Carl Zeiss AG in the amount of €400 million at an interest rate of 3.66% p.a., due in full no later than 3 years starting from the disbursement. The loan can be repaid in part or in full at any time ahead of the maturity date.

The Supervisory Board of Carl Zeiss Meditec AG has approved the conclusion of the loan agreement.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at


Share this page